| Year | Title | Author(s) |
|---|
| 2014 |
Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden
Bmc Cancer |
Abubaker, K Luwor, RB Zhu, HJ McNally, O Quinn, MA Burns, CJ Thompson, EW Findlay, JK Ahmed, N |
| 2015 |
Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9
Bioorganic & Medicinal Chemistry |
Phillipson, LJ Segal, DH Nero, TL Parker, MW Wan, SS de Silva, M Guthridge, MA Wei, AH Burns, CJ |
| 2015 |
BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells
Sci Rep |
Baker, EK Taylor, S Gupte, A Sharp, PP Walia, M Walsh, NC Zannettino, ACW Chalk, AM Burns, CJ Walkley, CR |
| 2017 |
Repurposed JAK1/JAK2 Inhibitor Reverses Established Autoimmune Insulitis in NOD Mice
Diabetes |
Trivedi, PM Graham, KL Scott, NA Jenkins, MR Majaw, S Sutherland, RM Fynch, S Lew, AM Burns, CJ Krishnamurthy, B Brodnicki, TC Mannering, SI Kay, TW Thomas, HE |
| 2017 |
Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain Inhibitors
Acs Med. Chem. Lett. |
Sharp, PP Garnier, JM Hatfaludi, T Xu, Z Segal, D Jarman, KE Jousset, H Garnham, A Feutrill, JT Cuzzupe, A Hall, P Taylor, S Walkley, CR Tyler, D Dawson, MA Czabotar, P Wilks, AF Glaser, S Huang, DCS Burns, CJ |